Citadel Advisors’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-21,600
| Closed | -$32K | – | 14244 |
|
|
2022
Q2 | $32K | Sell |
21,600
-4,500
| -17% | -$3.31K | ﹤0.01% | 12191 |
|
|
2022
Q1 | $30K | Buy |
26,100
+4,600
| +21% | +$7.5K | ﹤0.01% | 13115 |
|
|
2021
Q4 | $54K | Sell |
21,500
-23,500
| -52% | -$92.3K | ﹤0.01% | 13214 |
|
|
2021
Q3 | $230K | Buy |
45,000
+14,800
| +49% | +$89.9K | ﹤0.01% | 11677 |
|
|
2021
Q2 | $251K | Buy |
30,200
+16,300
| +117% | +$137K | ﹤0.01% | 11692 |
|
|
2021
Q1 | $121K | Sell |
13,900
-8,500
| -38% | -$88K | ﹤0.01% | 12288 |
|
|
2020
Q4 | $243K | Buy |
+22,400
| New | +$276K | ﹤0.01% | 9446 |
|
|
2020
Q3 | – | Sell |
-14,400
| Closed | -$231K | – | 11008 |
|
|
2020
Q2 | $231K | Sell |
14,400
-9,900
| -41% | -$173K | ﹤0.01% | 8326 |
|
|
2020
Q1 | $377K | Buy |
24,300
+15,100
| +164% | +$324K | ﹤0.01% | 6927 |
|
|
2019
Q4 | $226K | Sell |
9,200
-3,500
| -28% | -$52K | ﹤0.01% | 8007 |
|
|
2019
Q3 | $131K | Sell |
12,700
-4,700
| -27% | -$59.3K | ﹤0.01% | 8360 |
|
|
2019
Q2 | $218K | Buy |
+17,400
| New | +$224K | ﹤0.01% | 8070 |
|
|
2018
Q1 | – | Sell |
-12,500
| Closed | -$157K | – | 8980 |
|
|
2017
Q4 | $157K | Sell |
12,500
-1,700
| -12% | -$24.7K | ﹤0.01% | 7254 |
|
|
2017
Q3 | $271K | Buy |
+14,200
| New | +$217K | ﹤0.01% | 6224 |
|
|
2016
Q1 | – | Sell |
-5,700
| Closed | -$91K | – | 8350 |
|
|
2015
Q4 | $91K | Sell |
5,700
-5,300
| -48% | -$78.6K | ﹤0.01% | 6803 |
|
|
2015
Q3 | $141K | Buy |
11,000
+1,700
| +18% | +$34.3K | ﹤0.01% | 6577 |
|
|
2015
Q2 | $223K | Buy |
9,300
+6,800
| +272% | +$131K | ﹤0.01% | 6177 |
|
|
2015
Q1 | $47K | Buy |
2,500
+1,700
| +213% | +$35.1K | ﹤0.01% | 7422 |
|
|
2014
Q4 | $15K | Sell |
800
-900
| -53% | -$21K | ﹤0.01% | 7989 |
|
|
2014
Q3 | $46K | Buy |
1,700
+1,100
| +183% | +$34.2K | ﹤0.01% | 6948 |
|
|
2014
Q2 | $19K | Buy |
+600
| New | +$14.1K | ﹤0.01% | 7320 |
|
Other funds holding EPZM
Citadel Advisors's EPZM Position: Q3 2022 in Review
Citadel Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 691,458 shares — an estimated $1.02M sold.
Citadel Advisors first reported a position in EPZM in Q2 2014 and held it in 26 quarters. The position peaked at $11M in Q2 2018. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Citadel Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Citadel Advisors sold 691,458 Epizyme, Inc shares in Q3 2022, an estimated $1.02M.
- Citadel Advisors first reported a position in Epizyme, Inc in Q2 2014 and held it in 26 quarters.
- Citadel Advisors's Epizyme, Inc position peaked at $11M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.